New drug combo aims to shrink Hard-to-Treat thymic tumors before surgery
NCT ID NCT07479628
First seen Mar 20, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This phase II trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation before surgery can shrink tumors in people with locally advanced thymic carcinoma. About 31 participants will receive 2-4 cycles of this combination, then have surgery if the tumor shrinks enough. After surgery, they will continue adebrelimab for up to one year to help prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.